Scholars Central

Conference abstractPublished 18 Jul 2019

Status of biosimilars in India

Authors: Anjana Male

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Biosimilars drugs are organic products that are having similar identical in pharmacodynamic and pharmacotherapeutic action to that of the branded drugs but can be available at a cheaper cost. Current scenario of biosimilars in Indian industry has its first massive break in 1984. Biosimilars market place in India presently include eight biosimilars, the main aim of introducing biosimilars drugs in Indian market is to increase patient access to biological therapy and to reduce health care cost. In India biosimilar has engrossed large investments in the areas of research, clinical trials and manufacturing. The expiry of patent protection for many biological drugs has given the scope for development of biosimilar drugs with low cost and high therapeutic action. Biosimilar drugs are facing many challenges for getting into market as well as approval process is more complicated too. India being one of the most preferred manufacturing destinations of biosimilar drugs.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Pharmaceutica Analytica Acta.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutica Analytica Acta
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Anjana Male”